This prospective pilot study evaluated whether low preoperative cerebral tissue oxygen saturation is associated with unfavourable outcomes after major elective non-cardiac surgery. Eighty-one patients over 60 years of age, American Society of Anesthesiologists physical status 3 or 4, were recruited. Resting cerebral tissue oxygen saturation was recorded on room air, and after oxygen supplementation, using cerebral oximetry. The primary outcome was 30-day major adverse event of combined mortality or severe morbidity, and the secondary outcome was 30-day new disability. Eleven patients (13.6%) suffered a major adverse event, and 28 patients (34.6%) experienced new disability. Room air cerebral tissue oxygen saturation was significantly different between patients who had a major adverse event, 67% (95% confidence interval [CI] 65-70) versus unaffected, 71% (95% CI 70-72; P=0.04). No statistical difference was found between patients for new disability (range 70%-74%; P=0.73). Room air cerebral tissue oxygen saturation was significantly associated with major adverse events (odds ratio 1.36 (95% CI 1.03-1.79), P=0.03). Saturation levels ≤68% carried a positive likelihood ratio of 2.2 for death or severe morbidity, P=0.04. A definitive trial is required to confirm if cerebral oximetry can be used to stratify the cardiovascular risk of patients presenting for non-cardiac surgery.
Introduction
Cerebral tissue oxygen saturation can be non-invasively estimated using near-infrared wavelength light. Current cerebral oximeters rely on the property that near infrared light is attenuated by oxyhaemoglobin and deoxyhaemoglobin chromophores in cerebral tissue. Knowledge of the chromophore absorption coefficient, the light pathlength through human skull and cerebral tissue, and an estimation of light scattering and non-haem chromophore absorption, allows calculation of cerebral tissue oxygen saturation (ScO 2 ) 1 .
ScO 2 values represent a balance between oxygen extraction and oxygen delivery, where the latter is determined by variables including cerebral blood flow, cardiac output, pulmonary function, inspired oxygen concentration, arterial oxygen saturation, and haemoglobin concentration. In a preoperative context, ScO 2 measurements taken at rest, in room air, and before medications, represent a steady state situation where oxygen consumption is stable. Low preoperative ScO 2 (preScO 2 ) values therefore suggest significant systemic cardiovascular compromise, as cerebral perfusion is relatively preserved compared to systemic perfusion. Low preScO 2 could thus be viewed as a surrogate for perioperative cardiovascular risk, as it implies an inability to increase oxygen extraction in response to increased demands with surgery.
There is some evidence for an association between preScO 2 and outcomes in the cardiac anaesthesia literature. In adult cardiac surgery, room air preScO 2 ≤60% was an independent risk factor for 30-day and one-year mortality, and was as useful as cardiac biochemical markers for prognosis 2 . Similarly, mortality was associated with room air preScO 2 ≤50% in paediatric cardiac surgery 3 . Postoperative delirium after on-pump cardiac surgery was also associated with preScO 2 ≤58% 4 .
In contrast, the evidence for a relationship between unfavourable outcomes and low preScO 2 after non-cardiac surgery is unclear. Furthermore, preScO 2 values cannot be generalised between different cerebral oximeters due to dissimilar sensor designs and algorithm assumptions 5, 6 .
We therefore designed a pilot study to determine if preScO 2 , measured in both room air and after oxygen supplementation, in an elderly, high-risk patient population admitted for major non-cardiac surgery, is associated with unfavourable outcomes. The aims were to test the hypothesis that preScO 2 could be used as a cardiovascular risk screening tool, determine the preScO 2 thresholds for the oximeter used in our study, and data collection pertinent to conducting a definitive trial. The primary outcome was 30-day major adverse event of mortality or severe morbidity, and secondary outcome was 30-day new onset functional disability.
Methods
This prospective observational study was approved by the South Western Sydney Local Health District Human Research and Ethics Committee (HREC/13/LPOOL/309) and undertaken in Liverpool Hospital, Sydney, Australia. Patients were co-recruited when enrolled for the multinational, multicentre randomised controlled trial on the effect of depth of anaesthesia on postoperative outcomes after major surgery (The BALANCED Anaesthesia Study, ANZCTR number 12612000632897, HREC/12/MH/385). Inclusion criteria, exclusion criteria, intraoperative management and outcome measures were thus identical to the BALANCED study protocol 7, 8 .
Eligible patients were those admitted for elective major non-cardiac surgery (estimated duration of surgery ≥ two hours, ≥ two days postoperative admission), ≥60 years old, American Society of Anesthesiologists physical status (ASA PS) 3 or 4, and planned to receive a general anaesthetic with a volatile agent, with or without a regional anaesthesia technique. Patients previously enrolled in the study were ineligible.
Patients were approached in the pre-anaesthetic clinic, and after written informed consent for both the BALANCED study and this substudy, were co-recruited. Baseline preoperative data were collected, including the modified Charlson score 9 , comorbidities, medication history, haemoglobin, creatinine and albumin levels.
In the anaesthetic procedure bay, a study team member cleaned the patient's forehead with 70% alcoholimpregnated swabs and dried with gauze. Non-invasive cerebral oximetry sensors were placed bilaterally on the patient's forehead. To standardise preScO 2 measurements and to minimise contamination, the following steps were taken: sensors were sited on the frontal prominence between the midline and temporalis muscles laterally and just below the hairline, to respectively avoid the sagittal venous sinus, muscle, and frontal air sinuses 10, 11 . The same oximeter was used for all measurements (EQUANOX™ X-100, Nonin Medical, Plymouth, MN, USA) and recordings were performed prior to any medications, including vasopressors 6, 12 , being administered.
On room air, the 'baseline preScO 2 ' value was recorded from both cerebral hemispheres once saturation values did not change, or at the end of five minutes of undisturbed rest. A Hudson mask was then placed over the patient's face and oxygen administered at 6 litres/minute. The 'supplemented preScO 2 ' value was recorded for both hemispheres once the saturation values did not change, or at the end of five minutes of oxygenation.
Intraoperative management was within the parameters of the BALANCED protocol: exclusion criteria included a technique using total intravenous anaesthesia with propofol, use of nitrous oxide, and ketamine infusions ≥25 mg/hour. Mean arterial pressure was maintained within an a priori target band. Patients were randomised into a low (30-40) or high (45-55) bispectral index target, and this depth of anaesthesia was maintained for at least 90% of the intraoperative period.
All outcomes for this study were defined BALANCED study endpoints. Primary outcome for this study was a dichotomised 30-day major adverse event. This was the BALANCED study primary endpoint of all-cause mortality, and combined with the following morbidity endpoints: 1.Acute myocardial infarction, defined by a typical rise in troponin level, or typical fall in elevated troponin, or rapid rise and fall of creatine kinase MB isoenzyme. In addition, one of the following was required: ischaemic symptoms, pathological Q waves, electrocardiographic evidence of ischaemia, coronary artery revascularisation procedure, or new regional wall motion abnormality on echocardiography or myocardial perfusion scan; 2.cardiac arrest, defined as successful resuscitation from either documented or presumed ventricular fibrillation, sustained ventricular tachycardia, or asystole; 3.stroke, defined as cerebral infarction or haemorrhage on computed tomography or magnetic resonance imaging scan, or new neurological signs lasting more than 24 hours; 4.pulmonary embolism, defined as a high probability ventilation-perfusion scan, positive spiral computed tomography or positive pulmonary angiography; 5.sepsis, meeting the definition of systemic inflammatory response syndrome and a positive blood culture; 6.surgical site infection, defined as purulent discharge from the wound and/or a positive microbial culture; and 7.unplanned intensive care unit admission.
The secondary outcome for this study was the BALANCED study endpoint of 30-day new onset disability, measured by the 12-item World Health Organization Disability Assessment Schedule 2.0 (WHODAS). An increase of ≥4 points in scores after surgery was deemed as new onset disability, while <4 points was classified as unchanged patient function, and recorded as a dichotomous outcome. This is numerically equivalent to the 8% change in scores suggested by Shulman et al 13 as the threshold for new onset disability, in their study of WHODAS in surgical patients.
There were two previous studies on preScO 2 and noncardiac surgery, but with insufficient data to allow sample size calculation for mortality, morbidity, or new onset disability outcomes 14, 15 . Story et al's study had the most comparable patient population (similar age group, 65% patients were ASA PS 3 or 4, included 34% emergency surgery cases, Australasian data) 16 ; 30-day mortality rate was 5.2% and 30-day morbidity rate was 20.1%. For the functional status outcome, 18% of patients suffered a new onset disability at three months postoperatively 13 . For this pilot study, we therefore aimed to recruit a convenience sample size of 80 patients, expecting approximately four deaths and 16 complications, and more than 16 newly disabled patients at the 30-day postoperative follow up.
For statistical analysis, continuous data was tested for normality with the Shapiro-Wilk test, and results presented as mean (standard deviation, SD) or median (interquartile range, IQR [range]). PreScO 2 measurements were averaged from both hemispheres prior to analysis. T-tests, Mann-Whitney U tests, and Fisher's exact tests were used to compare preoperative patient characteristics to the dichotomous primary outcome (presence or absence of a major adverse event) and dichotomous secondary outcome (new onset or unchanged WHODAS disability status). Randomisation of patients to low and high bispectral index occurred due to co-recruitment with the BALANCED study. As a known confounder, analysis was performed on group allocation against outcomes.
Baseline and supplemented preScO 2 measurements were compared against each outcome using repeated measures mixed analysis of variance (ANOVA). Any significant results were further analysed using univariate ANOVA post hoc tests with a Bonferroni correction for multiple pairwise comparisons. All preoperative characteristics were analysed with point-biserial bivariate correlation for each of the primary and secondary outcomes. The five factors with the highest correlation were then entered into a binary logistic regression model, and reported as an odds ratio with a 95% confidence interval (CI). Receiver operating characteristic was performed for both baseline and supplemented preScO 2 values against outcomes, and reported as the area under the curve (AUC) with a 95% CI. Statistical analysis was performed using SPSS version 23 (IBM Corp, Armonk, NY, USA). Statistical significance was determined by two-tailed analysis, P <0.05.
Results
Eighty-one patients were recruited between June 2014 and September 2015. One patient withdrew after surgery and before the 30-day follow-up date. Data for 80 patients were thus available for analysis. Patients had multiple and significant comorbidities, with a median modified Charlson score of 6 (IQR [range] 5-7 [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] ). Other preoperative characteristics are reported in Table 1 (on next page).
There were eleven patients (13.6%) who suffered a major adverse event at 30 days: three deaths, one myocardial infarction, two pulmonary embolic events, two surgical site infections, one postoperative stroke and two unplanned intensive care unit admissions. Twenty-eight patients (34.6%) were classified as having new onset disability at 30 days. Lower haemoglobin and albumin were significant for 30-day new onset disability, but no preoperative characteristics were significant for the major adverse event outcome. There was no statistical difference between patients allocated to low or high depth of anaesthesia and postoperative outcomes ( Table 1) .
Patients underwent multiple types of surgery. Vascular surgery included peripheral bypass and endarterectomy surgery, and abdominal aortic aneurysm repair. Thoracic patients underwent lobectomy or pneumonectomy surgery via thoracotomy incisions. Intra-abdominal surgery varied by specialty, and included major colorectal, major urological, hepatic, oesophageal, pancreatic, gastric, and gynaecologyoncology surgery. Patients in the 'Other' category were eligible spinal (multiple level vertebral fusion, vertebrectomy), and major head and neck dissections for cancer ( Table 1) . Type of surgery did not differentiate patients from suffering either outcome of major adverse event or new disability.
There was a statistically significant difference in baseline preScO 2 between patients suffering a major adverse event, Figure 1 : Baseline room air and oxygen-supplemented preoperative cerebral tissue oxygen saturation (preScO 2 ) values for the major adverse events outcome. Comparison between patients who were unaffected ( ) and those who died or suffered morbidity at 30 days ( ). * There was a significant difference between the unaffected group, baseline preScO 2 71% (95% CI 70-72) versus adverse outcome group, baseline preScO 2 67% (95% CI 650), P=0.04. All groups had a significant increase in preScO 2 values from baseline to supplemented (P <0.001). Figure 1 ). There was no statistical difference in baseline preScO 2 between patients with new onset disability, 70% (95% CI 68-72), and those with unchanged functional status, 70% (95% CI 69-72), P=0.67 ( Table 2 and Figure 2 ). Supplementation with oxygen statistically improved preScO 2 values in all patient cohorts in both outcomes of major adverse event or new disability. The preScO 2 values were 67% to 71% at baseline, improving to 71% to 74% with oxygen, all P values <0.001 ( Table 2 , Figures 1 and 2) . There was no statistical difference between supplemented preScO 2 values between patients with presence of major adverse event, 71% (95% CI 68-74), versus patients without this outcome, 74% (95% CI 73-75), P=0.07. Similarly, there was no statistical difference in supplemented preScO 2 values for patients with new onset disability, 73% (95% CI 71-75), versus unchanged functional status, 74% (95% CI 72-75), P=0.79.
The five preoperative characteristics with the highest correlation for each outcome is reported in Table 3 . Baseline preScO 2 was significantly correlated with death/morbidity (r = -0.25, P=0.02), and albumin was significant for new onset disability (r = -0.35, P=0.02). The binary logistic regression model was significant (χ 2 (5) = 13.5, P=0.02) and explained 44.2% of variance in the combined death/morbidity outcome and correctly classified 84.8% of cases. Only lower baseline preScO 2 was significant, with lower preScO 2 values associated with an odds ratio of 1.36 (95% CI 1.03-1.79, P=0.03) for death/morbidity. For the new onset disability outcome, the binary logistic regression model was significant (χ 2 (7) = 16.6, P=0.02) and explained 41.3% of variance and correctly classified 80.4% of cases. None of the input factors were significant.
The receiver operating characteristic for 30-day major adverse event outcome and baseline preScO 2 was significant, with an area under the curve (AUC) of 0.70 (95% CI 0.52-0.87, P=0.04). A baseline preScO 2 value of 68% has 64% sensitivity and 71% specificity, and a positive likelihood Comparison between patients who were unchanged ( ) and those who had new onset disability at 30 days ( ). * There was a significant increase in preScO 2 between time measurements (P <0.001), but no statistical difference between groups within each time period (P=0.67-0.79). 
Discussion
This pilot study was designed to test the hypothesis that low preoperative ScO 2 was associated with worse postoperative outcomes after non-cardiac surgery, as has been previously observed after cardiac anaesthesia. In our study, we found that the association between low room air preScO 2 and 30-day mortality and morbidity was statistically significant. Baseline preScO 2 levels of less than 68%, measured by the EQUANOX X-100 oximeter, were more than twice as likely to be associated with these adverse outcomes. There were no associations between baseline preScO 2 levels and the secondary outcome of new onset functional disability. ScO 2 levels measured after oxygen supplementation did not distinguish patients from either outcome of major adverse event or new disability.
In our study, we recruited elderly patients with a high degree of comorbidity, undergoing elective major noncardiac surgery. The burden of complications was high at one month postoperatively in this patient population: 13.6% of patients either died or suffered major morbidity, and 34.6% of patients experienced a new disability as defined using the WHODAS tool.
Cerebral oximetry is predominantly used intraoperatively, and there are relatively few publications on the clinical utility of preScO 2 . Through this pilot study on preScO 2 and risk of postoperative outcomes, we sought to address these issues: 1) evidence for preScO 2 and cardiovascular risk; 2) evidence for preScO 2 and outcomes; 3) implications; and 4) limitations.
There are multiple studies of preScO 2 as a surrogate of overall cardiovascular status, and comparable to other indices of cardiovascular function 17 . For example, preScO 2 has been correlated with jugular mixed venous and central venous oxygen saturation, cardiac output measured via pulmonary artery catheter, transoesophageal echocardiography and angiography-derived estimates of left ventricular function [18] [19] [20] . Low preScO 2 was associated with increased mortality, sudden cardiac death, or worsening heart failure in patients with known ischaemic heart disease 21 . Preoperative ScO 2 also correlates with oxygen uptake at maximal aerobic capacity and anaerobic threshold during cardiopulmonary exercise testing (CPX) 22 . This last correlation is important as recently published consensus guidelines reaffirmed the evidence for CPX indices as predictive for outcomes after major noncardiac surgery 23 .
In contrast to cardiac surgery, there are few studies of preScO 2 and outcomes after non-cardiac surgery. In a study of 20 patients, aged >65 years, ASA PS 1 or 2, admitted for elective abdominal surgery, preScO 2 ≤60% (INVOS™ 3100 oximeter, Covidien Corporation, Troy, MI, USA) was associated with an increased rate of postoperative delirium 15 . In another study, 60 patients aged >65 years, ASA PS 2 or 3, were admitted for elective abdominal surgery. Preoperative ScO 2 ≤63% (INVOS 4100 oximeter, Covidien Corporation, Troy, MI, USA) was weakly correlated (r 2 = 0.19) with increased length of admission. Cardiac, pulmonary, neurological and surgical complications were recorded, but were not defined or analysed against preScO 2 values 14 . In both studies preScO 2 was not associated with the primary outcome of postoperative cognitive dysfunction, but this was measured with tools not validated for this endpoint. We therefore present the first observation of a relationship between baseline preScO 2 and death/morbidity after non-cardiac surgery.
The role for preScO 2 is in the pre-anaesthetic clinic. Cerebral oximetry can be used as a risk assessment tool to assist decision-making for optimising patients for surgery, requesting higher level postoperative care, or prompting a discussion on the appropriateness of surgery. Oximetry could be an adjunct to, or a replacement for, existing functional exercise tests such as CPX or the six minute walk test. While CPX thresholds do allow postoperative risk stratification, CPX testing has the disadvantage of requiring specialised equipment and trained staff. A significant proportion of patients also cannot perform CPX adequately; up to 40% of elective joint replacement patients are unable to perform lower limb exercise 24 . Cerebral oximetry has the advantages of being simple, mobile, fast, non-invasive, and able to be applied to all patients.
For use as a preoperative screening tool, preScO 2 values have moderate sensitivity and specificity. In our pilot study, baseline preScO 2 ≤68% has a 64% sensitivity and 71% specificity for death or morbidity. Increasing the cutoff to 72%, equivalent to the highest baseline preScO 2 of the patients who did not suffer a major adverse event, improves sensitivity to 91% but specificity deceases to 45%. Comparable values in cardiac surgery are: preScO 2 ≤53% for 30-day mortality (75% sensitivity and 79% specificity), and preScO 2 ≤60% for 30-day major adverse events (56% sensitivity and 71% specificity) (INVOS 5100 oximeter, Covidien Corporation, Troy, MI, USA) 2 .
We thus present encouraging results that suggest preScO 2 has both biological plausibility and ability to detect patients at risk of postoperative complications. To test baseline and supplemented preScO 2 versus a death/morbidity outcome in a definitive trial, using repeated measures ANOVA, we calculate that a sample size of 400 patients will provide a significance of <0.01, to detect a 0.20 effect size, with a power of 0.99. Furthermore, a larger trial will allow stratification of preScO 2 values into low, intermediate, and higher risk bands for adverse outcomes, rather than a single numerical threshold.
There are two important limitations in this study. We recruited a specific subset of elderly patients classified as ASA PS 3 or 4, but still deemed to have sufficient cardiovascular reserve to undergo major surgery. As an example of bias, we found that baseline preScO 2 was the only significant preoperative variable for major adverse events, and other normally significant variables such as age and Charlson score were not. Similarly, oxygenation significantly improved all baseline preScO 2 measurements, but did not differentiate our patients from outcomes, unlike results from studies in cardiac surgery 2 . As cerebral perfusion is relatively well preserved until advanced stages of cardiovascular disease, we probably excluded patients with oxygen-refractory preScO 2 .
Another limitation may be the use of the WHODAS tool. WHODAS assesses six domains of function and participation in society 25 , and has recently been validated in post-surgical patients 13, 26 . However, a patient with a midline laparotomy may not perform household chores simply due to the surgical incision, but a patient with perioperative stroke is equally unable to perform chores. This lack of diagnostic discrimination may explain the lack of association of preScO 2 and functional status in our results, as new onset disability may be caused by factors unrelated to cardiovascular risk.
Conclusion
In conclusion, we found that room air, preoperative baseline ScO 2 is associated with 30-day major adverse events, with lower values associated with an odds ratio of 1.36 as an independent preoperative variable for this outcome. Baseline preScO 2 values ≤68% were associated with more than twice the likelihood of mortality and morbidity. The results of this study are preliminary, and a larger trial is required to confirm these findings as well as to clarify the role of cerebral oximetry as a preoperative risk screening tool.
